E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Thromboembolism in subjects who have undergone an elective primary unilateral total knee replacement |
Tromboembolismo en sujetos que hayan sido sometidos a remplazo total de rodilla unilateral primario electivo |
|
E.1.1.1 | Medical condition in easily understood language |
Prevention of forming a blood clot following surgery for replacement of the knee |
Prevención en la formación de coágulos de sangre después de cirugía para reemplazo de rodilla |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Part 1: The primary objective is to assess the safety and tolerability of JNJ-64179375 for each dose level for dose escalation within Part 1 and any bleeding events (the composite of major, clinically relevant nonmajor, and minimal bleeding events) for the selection of doses for Part 2.
Part 2: The primary objective is to assess the efficacy dose response of JNJ-64179375 for the prevention of total venous thromboembolism (VTE) (proximal and/or distal deep-vein thrombosis (DVT) [asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic], nonfatal PE, or any death). |
Parte 1: El objetivo principal es evaluar la seguridad y la tolerabilidad de JNJ-64179375 en cada nivel de dosis durante el incremento escalonado de la dosis en la parte 1 y los acontecimientos hemorrágicos (la combinación de acontecimientos hemorrágicos graves, acontecimientos hemorrágicos no graves clínicamente relevantes y acontecimientos hemorrágicos mínimos) para la selección de las dosis para la parte 2.
Parte 2: El objetivo principal es evaluar la respuesta de eficacia a la dosis de JNJ-64179375 para la prevención de la TEV total (TVP proximal y/o distal [asintomática confirmada mediante flebografía de la pierna operada o sintomática confirmada de manera objetiva], la EP no mortal o cualquier muerte). |
|
E.2.2 | Secondary objectives of the trial |
Part 1 : • to assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint of any bleeding events, the composite endpoint of major or clinically relevant nonmajor bleeding events, and the individual components of the composite endpoint of any bleeding event • to assess the dose response of JNJ-64179375 for the prevention of total VTE and the individual components of total VTE Part 2: • to assess the dose response of JNJ-64179375 for the occurrence of the composite endpoint of any bleeding events, the composite endpoint of major or clinically relevant nonmajor bleeding events, and the individual components of the composite endpoint of any bleeding event • to assess the dose response of JNJ-64179375 for the prevention of major VTE and the individual components of the total VTE endpoint
Please refer to the protocol for further secondary objectives common to both Part 1 and Part 2 |
Parte 1: • Evaluar la respuesta a la dosis de JNJ-64179375 en relación con la incidencia del criterio de valoración combinado de cualquier acontecimiento hemorrágico, el criterio de valoración combinado de acontecimientos hemorrágicos graves o no graves clínicamente relevantes y los componentes • Evaluar la respuesta a la dosis de JNJ-64179375 en relación con la prevención del tromboembolismo venoso total (TEV) y los componentes individuales de la TEV total Parte 2: • Evaluar la dosis-respuesta de JNJ-64179375 en relación con la incidencia del criterio de valoración combinado de cualquier acontecimiento hemorrágico, el criterio de valoración combinado de acontecimientos hemorrágicos graves o no graves clínicamente relevantes y los componentes individuales del criterio de valoración combinado de cualquier acontecimiento hemorrágico
Ver protocolo para más objetivos secundarios comunes de la Parte 1 y Parte 2 |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female of non-childbearing potential - At least 50 years of age or older - Weight 40 kg to 150 kg - Medically appropriate for postoperative anticoagulant prophylaxis - Has undergone an elective primary unilateral TKR |
- Varones o mujeres sin capacidad de procrear - De al menos 50 o más años de edad - Peso ≥ 40 kg a ≤ 150 kg - Médicamente adecuados para profilaxis anticoagulante postoperatoria - Haberse sometido a ATR unilateral primaria programada |
|
E.4 | Principal exclusion criteria |
- Any condition for which the use of apixaban is not recommended in the opinion of the investigator - Bilateral, revision or unicompartmental procedure - Known or suspected hypersensitivity or intolerance to any biologic medication or known allergies or clinically significant reactions to murine, chimeric, or human proteins, monoclonal antibodies or antibody fragments, or any of the excipients of JNJ-64179375 - Unable to undergo venography - Known previous DVT in either lower extremity - Any preplanned invasive procedure (eg, surgery, colonoscopy) up to Week 18 for which anticoagulant or antiplatelet therapy would be interrupted - Planned use of intermittent pneumatic compression after randomization |
- Cualquier circunstancia o enfermedad en la que no se recomiende el uso de apixaban en opinión del investigador - Procedimiento bilateral, de revisión o unicompartimental - Certeza o sospecha de hipersensibilidad o intolerancia a cualquier fármaco biológico o alergias conocidas o reacciones clínicamente importantes a proteínas murinas, quiméricas o humanas, anticuerpos monoclonales o fragmentos de anticuerpos, o a alguno de los excipientes de JNJ-64179375 - Incapacidad para someterse a una flebografía - TVP previa confirmada en una de las extremidades inferiores - Cualquier procedimiento invasivo programado de antemano (p. ej., cirugía, colonoscopia) hasta la semana 18 para el que deba interrumpirse el tratamiento anticoagulante o antiagregante plaquetario - Uso previsto de compresión neumática intermitente después de la aleatorización |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The endpoints of the study will be the same for Parts 1 and 2 although the focus of Part 1 will be primarily dose escalation based on safety while the focus of Part 2 will primarily be the assessment of dose response in both safety and efficacy.
Common Endpoints in Parts 1 and 2
Primary Safety Endpoint The primary safety endpoint is any bleeding event defined as the composite of major, clinically relevant nonmajor, and minimal bleeding events assessed through the Day 10-14 visit.
Primary Efficacy Endpoint The primary efficacy endpoint is total VTE, defined as the composite of proximal and/or distal DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death assessed through the Day 10-14 visit. |
Los criterios de valoración del estudio serán los mismos en las partes 1 y 2, pero el centro de interés de la parte 1 será primordialmente el incremento escalonado de la dosis basado en la seguridad, mientras que el centro de interés de la parte 2 será primordialmente la evaluación de la respuesta a la dosis en la seguridad y la eficacia.Criterios de valoración comunes en partes 1 y 2
Criterios de valoración comunes en las partes 1 y 2
Criterio de valoración principal de la seguridad El criterio de valoración principal de la seguridad es cualquier acontecimiento hemorrágico definido como la combinación de acontecimientos hemorrágicos graves, no graves clínicamente importantes y mínimos hasta la visita del día 10-14.
Criterio de valoración principal de la eficacia criterio de valoración principal de la eficacia es la TEV total, definida como la combinación de TVP proximal y/o distal (asintomática confirmada mediante flebografía de la pierna operada o sintomática confirmada de manera objetiva), EP no mortal o cualquier muerte hasta la visita del día 10-14. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Through the Day 10-14 visit. |
Hasta la visita del día 10-14 |
|
E.5.2 | Secondary end point(s) |
Key Secondary Endpoints The key secondary endpoints are the assessment of the primary endpoints through the Week 18 visit, and: • All individual components of the primary safety endpoint (major bleeding, clinically relevant nonmajor bleeding, and minimal bleeding) • Composite of major and clinically relevant nonmajor bleeding • Major VTE, a composite of proximal DVT (asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic), nonfatal PE, or any death • All individual components of the primary efficacy endpoint (ie, proximal and/or distal DVT [asymptomatic confirmed by venography assessment of the operated leg or objectively confirmed symptomatic], nonfatal PE, any death) Other Secondary Endpoints • Any wound or joint complication in the operated leg |
Criterios de valoración secundarios esenciales Los criterios de valoración secundarios esenciales son la evaluación de los criterios de valoración principales hasta la visita de la semana 18 y: • Todos los componentes individuales del criterio de valoración principal de la seguridad (hemorragia grave, hemorragia no grave clínicamente importante y hemorragia mínima) • Combinación de hemorragia grave y hemorragia no grave clínicamente importante • TEV importante, una combinación de TVP proximal (asintomática confirmada mediante flebografía de la pierna operada o sintomática confirmada de manera objetiva), EP no mortal o cualquier muerte • Todos los componentes individuales del criterio de valoración principal de la eficacia (es decir, TVP proximal y/o distal [asintomática confirmada mediante flebografía de la pierna operada o sintomática confirmada de manera objetiva], EP no mortal o cualquier muerte) • Cualquier complicación de la herida o la articulación la pierna operada |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Through the Week 18 visit. |
hasta la visita de la semana 18 |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 11 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 13 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 74 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Argentina |
Belgium |
Brazil |
Bulgaria |
Canada |
Czech Republic |
Hungary |
Japan |
Latvia |
Lithuania |
Malaysia |
Poland |
Romania |
Russian Federation |
Spain |
Sweden |
Turkey |
Ukraine |
United States |
|
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit last subject |
Última visita del último sujeto |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 10 |
E.8.9.1 | In the Member State concerned days | 17 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 10 |
E.8.9.2 | In all countries concerned by the trial days | 17 |